JP2021512893A5 - - Google Patents

Info

Publication number
JP2021512893A5
JP2021512893A5 JP2020542546A JP2020542546A JP2021512893A5 JP 2021512893 A5 JP2021512893 A5 JP 2021512893A5 JP 2020542546 A JP2020542546 A JP 2020542546A JP 2020542546 A JP2020542546 A JP 2020542546A JP 2021512893 A5 JP2021512893 A5 JP 2021512893A5
Authority
JP
Japan
Prior art keywords
theta
degrees
approximately
polymorph
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512893A (ja
JP7550646B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017117 external-priority patent/WO2019157225A2/en
Publication of JP2021512893A publication Critical patent/JP2021512893A/ja
Publication of JP2021512893A5 publication Critical patent/JP2021512893A5/ja
Application granted granted Critical
Publication of JP7550646B2 publication Critical patent/JP7550646B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542546A 2018-02-08 2019-02-07 特定の化学物質、組成物、および方法 Active JP7550646B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628194P 2018-02-08 2018-02-08
US62/628,194 2018-02-08
PCT/US2019/017117 WO2019157225A2 (en) 2018-02-08 2019-02-07 Certain chemical entities, compositions, and methods

Publications (3)

Publication Number Publication Date
JP2021512893A JP2021512893A (ja) 2021-05-20
JP2021512893A5 true JP2021512893A5 (enExample) 2022-02-16
JP7550646B2 JP7550646B2 (ja) 2024-09-13

Family

ID=67549574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542546A Active JP7550646B2 (ja) 2018-02-08 2019-02-07 特定の化学物質、組成物、および方法

Country Status (13)

Country Link
US (1) US11465975B2 (enExample)
EP (1) EP3749310B1 (enExample)
JP (1) JP7550646B2 (enExample)
KR (1) KR20200143361A (enExample)
CN (1) CN112105365A (enExample)
AU (1) AU2019218893B2 (enExample)
CA (1) CA3090528A1 (enExample)
ES (1) ES3065300T3 (enExample)
IL (1) IL276476B2 (enExample)
PH (1) PH12020551193A1 (enExample)
PL (1) PL3749310T3 (enExample)
SG (1) SG11202007492XA (enExample)
WO (1) WO2019157225A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255434A4 (en) * 2020-12-02 2024-10-23 Neupharma, Inc. CERTAIN CHEMICALS, COMPOSITIONS AND PROCESSES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
WO2013032951A1 (en) * 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
LT2964638T (lt) * 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) * 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
CN108430990B (zh) * 2015-12-25 2020-08-25 山东轩竹医药科技有限公司 喹唑啉衍生物的晶体及其制备方法

Similar Documents

Publication Publication Date Title
TWI619694B (zh) 用於製備喹啉衍生物之方法
TWI704142B (zh) 抗癌劑1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)環丙胺的製備方法、及其藥物的結晶形及其鹽類
TWI417292B (zh) 2-甲基-2-〔4-(3-甲基-2酮-8-喹啉-3-基-2,3-二氫-咪唑并〔4,5-c〕喹啉-1-基)-苯基〕-丙腈之鹽及結晶型式
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
TWI705060B (zh) 一種mek激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法
JP6170146B2 (ja) チロシンキナーゼ阻害剤二マレイン酸塩のi型結晶およびその製造法
JP3665053B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
CA2588398A1 (en) Potassium salt of an hiv integrase inhibitor
EP1919893A2 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
KR102612379B1 (ko) 벤조푸란 유도체 자유 염기의 결정 및 제조 방법
EP3283491A1 (en) New forms of ixazomib citrate
WO2018007927A1 (en) Process for preparation of palbociclib
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
US6521642B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
TW202024078A (zh) Bet溴結構域(bromodomain)抑制劑之固體形式之製備方法
WO2019037591A1 (zh) 盐酸美法仑晶型及其制备方法与应用
TW201625582A (zh) 製備吡蟲啉(imidacloprid)多晶型的方法
US20020147221A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
WO2023068253A1 (ja) ベンゾチオフェン化合物の新規結晶形及びその製造方法
US20110184067A1 (en) O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
EP2019113A1 (en) New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
EP1768969B1 (en) Crystalline mycophenolate sodium
CN115397426A (zh) 伊布替尼葡糖糖酸内酯共晶体及其制备方法
US9328115B2 (en) Process for preparing meropenem trihydrate
WO2019029477A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法